Cambridge, UK 28th May 2008, Astex Therapeutics Limited announced today that data on two of its drug candidates, AT7519 and AT9283, will be presented at the ASCO Annual Conference, to be held 31st May - 3rd June 2008 in Chicago. Both of these candidates were discovered internally at Astex using its industry-leading fragment-based drug discovery platform, Pyramid™.
During the meeting Astex’s investigators will present the first clinical data from an international dose escalation study of AT7519, a potent cell cycle inhibitor. The results of this study demonstrate evidence of tumour shrinkage and biological activity in patients with advanced cancer treated with AT7519.
In addition, Astex’s investigators will make two presentations on AT9283, a multi-targeted kinase inhibitor. One will be the initial release of information from an ongoing Phase I dose escalation study in patients with refractory solid tumours. This study reveals evidence of significant disease stabilisation in a proportion of patients. The other will provide an update on the ongoing Phase I/II trial of AT9283 in patients with refractory leukaemia where early clinical activity has been reported.
Astex has a further five internal drug discovery programmes and is pursuing an additional five projects in partnership with leading pharmaceutical companies including Novartis, AstraZeneca and Boehringer Ingelheim.
Poster Discussion Presentations at the 2008 ASCO Annual Meeting
Poster Title: A dose escalation, pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumours Session Date: Saturday, May 31, 2008, 8:00 am – 12:00 pm Session ID: Developmental Therapeutics: Molecular Therapeutics Permanent Abstract Number: 3533
Poster Title: Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukaemia Session Date: Monday, June 2, 2008, 2:00 pm – 6:00 pm Session ID: Developmental Therapeutics: Cytotoxic Chemotherapy Permanent Abstract Number: 2518
Poster Title: A dose escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours Session Date: Monday, June 2, 2008, 2.00 pm – 6:00 pm Session ID: Developmental Therapeutics: Cytotoxic Chemotherapy Permanent Abstract Number: 2519
